Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Issues Emergency Use Authorization for GenMark Coronavirus Assay

FDA Issues Emergency Use Authorization for GenMark Coronavirus Assay

Mar 19, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration has issued Emergency Use Authorization for GenMark Diagnostics' ePlex SARS-CoV-2 Test, the firm announced Thursday evening.

The test qualitatively detects SARS-CoV-2 virus in nasopharyngeal swab samples and is for use on GenMark's sample-to-answer ePlex system, which is based on competitive DNA hybridization and electrochemical detection technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  2. FDA Issues New Guidance on SARS-CoV-2 Variants for Test Developers

  3. GenDx HLA Genotyping Products Receives Health Canada IVD Approval

  4. Azova Home Collection Kit Gets FDA EUA for Use With Fluidigm SARS-CoV-2 Test

  5. Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.